Dulaglutide has higher adherence and persistence than liraglutide and exenatide QW: 1-year follow-up from US real-world data

被引：0
|
作者：
Lando, L. Fernandez [1 ]
Mody, R. [1 ]
Huang, Q. [2 ]
Yu, M. [3 ]
Zhao, R. [2 ]
Patel, H. [1 ]
Grabner, M. [2 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] HealthCore Inc, Wilmington, DE USA
[3] Eli Lilly & Co, Toronto, ON, Canada
来源：
DIABETOLOGIA | 2018年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
760
引用
收藏
页码：S372 / S372
页数：1
相关论文
共 50 条
  • [1] Dulaglutide Has Higher Adherence and Persistence than Semaglutide and Exenatide QW: 6-Month Follow-Up from US Real-World Data
    Mody, Reema
    Yu, Maria
    Nepal, Bal K.
    Konig, Manige
    Grabner, Michael
    DIABETES, 2020, 69
  • [2] Higher Adherence and Persistence for Dulaglutide Compared with Oral Semaglutide at Six-Months Follow-Up with US Real-World Data
    Paczkowski, Rosirene
    Hoog, Meredith
    Peleshok, Jennifer
    Yu, Maria
    Ahong Huang
    Limone, Brendan
    Manjelievskaia, Janna
    DIABETES, 2022, 71
  • [3] Higher adherence and persistence for dulaglutide compared to oral semaglutide at 6-months follow-up with US real-world data
    Paczkowski, R.
    Hoog, M. M.
    Peleshok, J.
    Yu, M.
    Huang, A.
    Limone, B.
    Manjelievskaia, J.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S297 - S298
  • [4] Comparative Glycemic Effectiveness of Dulaglutide vs. Liraglutide and Exenatide QW in a US Real-World Setting
    Mody, Reema
    Huang, Qing
    Yu, Maria
    Patel, Hiren
    Zhao, Ruizhi
    Grabner, Michael
    Lando, Laura Fernandez
    DIABETES, 2018, 67
  • [5] Greater Adherence and Persistence with Injectable Dulaglutide Compared with Injectable Semaglutide at 1-Year Follow-up: Data from US Clinical Practice
    Mody, Reema
    Manjelievskaia, Janna
    Marchlewicz, Elizabeth H.
    Malik, Raleigh E.
    Zimmerman, Nicole M.
    Irwin, Debra E.
    Yu, Maria
    CLINICAL THERAPEUTICS, 2022, 44 (04) : 537 - +
  • [6] Greater Adherence and Persistence with Dulaglutide Compared with Semaglutide at 6-and 12-Months Follow-up in US Real-World Data
    Mody, Reema
    Manjelievskaia, Janna
    Yu, Maria
    Marchlewicz, Elizabeth H.
    Malik, Raleigh
    Zimmerman, Nicole
    Irwin, Debra E.
    DIABETES, 2021, 70
  • [7] Greater adherence and persistence with dulaglutide compared to injectable semaglutide at 6-and 12-months follow-up in US real-world data
    Mody, R.
    Manjelievskaia, J.
    Yu, M.
    Marchlewicz, E. H.
    Malik, R.
    Zimmerman, N. M.
    Irwin, D. E.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 232 - 232
  • [8] REAL-WORLD ADHERENCE AND PERSISTENCE AMONG ELDERLY PATIENTS WITH T2DM INITIATING DULAGLUTIDE VS. LIRAGLUTIDE OR EXENATIDE ONCE-EEKLY IN THE US
    Yu, M.
    Xu, Y.
    Kwan, A.
    Bunniran, S.
    Mody, R.
    Meah, Y.
    Changamire, T.
    Nair, R.
    VALUE IN HEALTH, 2019, 22 : S159 - S159
  • [9] Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States
    Mody, Reema
    Huang, Qing
    Yu, Maria
    Zhao, Ruizhi
    Patel, Hiren
    Grabner, Michael
    Lando, Laura Fernandez
    DIABETES OBESITY & METABOLISM, 2019, 21 (04): : 920 - 929
  • [10] Adherence and Persistence Among Patients with Parkinson's disease (PD) Initiating Istradefylline: 12-Month Follow-Up from US Real-World Data
    Joseph, R.
    Qian, J.
    Cummings, H.
    Chen, Y.
    Tewari, S.
    Soileau, M.
    MOVEMENT DISORDERS, 2024, 39 : S376 - S376
12345